Company's Profile
Race Oncology Limited is an Australian precision oncology company. They're developing a cancer drug called Zantrene, which targets the FTO protein. Zantrene is being explored as a potential therapy for melanoma and clear cell renal cell carcinoma, both linked to FTO. It acts as a precise, low-dose oncology agent and a cardio-protective chemotherapeutic. The drug also shows promise in reducing cardiotoxicity in acute myeloid leukemia, breast, and ovarian cancers. Race Oncology is dedicated to advancing Zantrene as a cancer treatment with a focus on improving chemotherapy outcomes.
